NextCure is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 82 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.42 |
|---|---|
| 52-week range | $0.98 - $2.57 |
| 50-day moving average | $1.60 |
| 200-day moving average | $1.49 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.22 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.42 from 2024-09-06
| 1 week (2024-08-30) | -3.40% |
|---|---|
| 1 month (2024-08-07) | -7.79% |
| 3 months (2024-06-07) | 2.16% |
| 6 months (2024-03-07) | -13.94% |
| 1 year (2023-09-07) | -2.07% |
|---|---|
| 2 years (2022-09-07) | -63.02% |
| 3 years (2021-09-07) | 7.64 |
| 5 years (2019-09-06) | 34.34 |
| Gross profit TTM | $-54,199,000 |
|---|---|
| Return on assets TTM | -31.09% |
| Return on equity TTM | -54.75% |
| Profit margin | 0% |
| Book value | $3.05 |
| Market Capitalization | $41.1 million |
TTM: trailing 12 months
We're not expecting NextCure to pay a dividend over the next 12 months.
Over the last 12 months, NextCure 's shares have ranged in value from as little as $0.98 up to $2.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure 's is 0.786. This would suggest that NextCure 's shares are less volatile than average (for this exchange).
NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.